FDA approval of Pixclara expands TLX growth beyond PSMA franchise
FDA cleared Pixclara (floretyrosine F18), Telix's glioma imaging agent, to differentiate recurrent/progressive tumors from treatment-related changes in adults and children as young as one month. Pixclara is now the only FDA-approved radiopharmaceutical for glioma in the U.S., with Phase 3 trials ongoing and potential expansion to brain metastases, signaling revenue diversification beyond TLX's PSMA PET franchise.
View signal analysis